21 Jun 2023 Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study Investors | Therapeutics
05 Jun 2023 Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake Investors | Therapeutics
01 Jun 2023 Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group Diagnostics | Investors
27 Apr 2023 First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study Investors | Therapeutics